Understand the source comparison
Peptides for Fibromyalgia Treatment Protocol Evidence Guide: Comparison
The following table compares the primary peptides under investigation for fibromyalgia-related pain and inflammation management based on published preclinical data and proposed clinical protocols. BPC-157 Mast cell stabilization, substance P reduction, VEGF up
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares the primary peptides under investigation for fibromyalgia-related pain and inflammation management based on published preclinical data and proposed clinical protocols.
- BPC-157
- Mast cell stabilization, substance P reduction, VEGF upregulation
- 250–500 mcg subcutaneous daily (divided doses)
- Animal models show reduced neuropathic pain scores and decreased substance P in dorsal root ganglia
- 4–6 weeks for initial response, 8–12 weeks for maximal benefit
- Strongest preclinical evidence for direct pain modulation through immune stabilization; short half-life requires consistent daily dosing
- Thymosin Beta-4
- Microglial deactivation, NF-κB inhibition, cytokine reduction (IL-1β, TNF-α)
- 2–5 mg subcutaneous twice weekly
- CNS neuroinflammation models demonstrate reduced microglial activation and allodynia
- 4–6 weeks for initial response, progressive improvement through week 12
- Potent anti-inflammatory profile in CNS; longer half-life allows less frequent administration; addresses central sensitization mechanism
- Thymalin
- T-cell regulation, systemic immune modulation
- 5–10 mg intramuscular 2–3× weekly
- Limited fibromyalgia-specific data; broader immune regulation evidence in autoimmune contexts
- 6–8 weeks
- Indirect mechanism through systemic immune balance; less fibromyalgia-specific research compared to BPC-157 or Tβ4
- Cerebrolysin
- Neurotrophic support, synaptic plasticity
- 5–10 mL intravenous 2–3× weekly
- Chronic pain studies show reduced pain intensity scores; mechanism involves nerve growth factor modulation
- 4–8 weeks
- Neurotrophic rather than anti-inflammatory; may address nerve dysfunction component; requires IV administration